FTC Reports an Increase in Anticompetitive Activities Among Drug Makers
According to the Federal Trade Commission, the number of potentially anticompetitive patent dispute settlements between branded and generic drug companies increased between 2011 and 2012.
In a new report issued by the Federal Trade Commission (FTC), FTC analysts reported that the number of potentially anticompetitive patent dispute settlements between branded and generic drug companies increased from 28 in 2011 to 40 in 2012. According to the report, companies filed a total of 140 final patent settlements. Of those, 40 settlements contained a payment to a generic manufacturer and also restricted the generic’s ability to market its product. In addition, the study found that in 19 of these settlements, branded firms may have used the promise that they would not develop or market an authorized generic as a payment to stall generic drug firms from marketing a competing product.
The FTC contends, in an accompanying press release, that patent settlements that include a payment delay generic entry by 17 months longer, on average, than those that do not include some form of payment. By delaying the entry of cheaper generics, they say, pay-for-delay deals cost Americans $3.5 billion annually and will add to the federal deficit. The FTC supports legislation that would restrict pay-for-delay settlements.
The Generic Pharmaceutical Association (GPhA) took issue with the FTC report. In a strongly worded statement, Ralph G. Neas, President and CEO of GPhA, said, "The FTC is wrong on the facts, wrong on the public policy and wrong on the law.” According to GPhA, settlements actually help bring affordable generic medicines to market sooner, resulting in billions of dollars in savings to consumers.
Neas concludes, “Like the FTC, we oppose anti-competitive and anti-consumer settlements. That's why we support provisions in the 2003 Medicare Modernization Act that require FTC review of all brand-generic patent settlements. An outright ban would have the unintended consequence of preventing pro-consumer settlements that actually allow generic competition sooner than if the generic company took the case to conclusion and lost—which is a possibility in every single patent case."
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Personalized CRISPR Therapy Successfully Treats Infant With Rare, Incurable CPS1 Deficiency
May 16th 2025A pediatric patient with a rare genetic disorder safely received a personalized CRISPR therapy, marking the first known case of a personalized CRISPR-based medicine administered to a single patient.
Top 10 Cleanroom Problems That Can Be Prevented via Preventative Maintenance (May 2025)
May 16th 2025Cleanrooms require strict environmental control to maintain sterility, prevent contamination, and ensure seamless operations. Without a proactive preventative maintenance (PM) program, various issues can arise, leading to costly downtime, contamination risks, and operational inefficiencies. Below are ten common cleanroom problems that can be effectively mitigated through proper PM practices.
